PGC‐1α activation as a therapeutic approach in mitochondrial disease
Citations Over TimeTop 10% of 2009 papers
Abstract
Mitochondria play a central role in cellular homeostasis. Hence, mitochondrial dysfunction resulting in impaired ATP supply is detrimental to cell viability and causes severe and often fatal disorders. Current treatment of these mitochondrial disorders is limited and mostly addresses the symptoms, but not the deficiency itself. Recent work in cell and animal models of mitochondrial disease shows that increased mitochondrial biogenesis can boost residual OXPHOS capacity and thereby prevent the bioenergetic crisis. In animal models, this strategy results in increased health and lifespan. Here, I review which mitochondrial processes are affected in known mitochondrial disorders and discuss why PGC-1alpha mediated mitochondrial biogenesis offers a promising venue for treatment of mitochondrial disorders.
Related Papers
- → Regulation of mitochondrial biogenesis(2010)1,115 cited
- → Mitochondrial Biogenesis as a Pharmacological Target: A New Approach to Acute and Chronic Diseases(2015)195 cited
- → Mitochondrial biogenesis and turnover(2008)152 cited
- → Abnormal mitochondrial dynamics and impaired mitochondrial biogenesis in trigeminal ganglion neurons in a rat model of migraine(2016)49 cited
- → Stimulatory Effects of Balanced Deep Sea Water on Mitochondrial Biogenesis and Function(2015)19 cited